![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/MANKIND.png)
Share the post "Mankind Pharma ‘s Q3 2024-25 Latest News: Profit Drops by 14.51% YoY"
Highlights
🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 1.61 % in the past year, decrease in net sales/revenue by -5.26 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 3.85 %. Marginal decrease of -33.98% in other income during this quarter. 🔹 Profit over the Year and quarter: Challenges in sustaining profitability for Mankind Pharma Limited. Profit dropped by -14.51 % Year to Year, Mankind Pharma Limited’s profitability dropped by -34.37 % Quarter to Quarter. 🔹 EPS over the Year and quarter: EPS declined by -14.88 % Year to Year. EPS decreased by -34.66 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 2358.566 Cr | Rs. 2529.74 Cr | Rs. 2396.57 Cr | -5.26 % | + 1.61 % |
| Expenses | Rs. 1755.46 Cr | Rs. 1777.71 Cr | Rs. 1655.64 Cr | -6.87 % | -5.69 % |
| Operating Profit | Rs. 603.11 Cr | Rs. 752.03 Cr | Rs. 740.93 Cr | -1.48 % | + 22.85 % |
| OPM % | 25.57 % | 29.73 % | 30.92 % | + 1.19 % | + 5.35 % |
| Other Income | Rs. 67.231 Cr | Rs. 105.76 Cr | Rs. 69.82 Cr | -33.98 % | + 3.85 % |
| Interest | Rs. 4.26 Cr | Rs. 1.92 Cr | Rs. 199.47 Cr | + 10289.06 % | + 4582.39 % |
| Depreciation | Rs. 89.73 Cr | Rs. 85.42 Cr | Rs. 87.03 Cr | + 1.88 % | -3.01 % |
| Profit before tax | Rs. 576.35 Cr | Rs. 770.45 Cr | Rs. 524.25 Cr | -31.96 % | -9.04 % |
| Tax % | 15.49 % | 21.81 % | 20.58 % | -1.23 % | + 5.09 % |
| Net Profit | Rs. 487.07 Cr | Rs. 634.43 Cr | Rs. 416.38 Cr | -34.37 % | -14.51 % |
| EPS in Rs | Rs. 12.14 | Rs. 15.81 | Rs. 10.33 | -34.66 % | -14.91 % |
Today, we’re looking at Mankind Pharma Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 1.61 %. However, it did see a marginal slip of -5.26 % from the previous quarter. Expenses decreased slightly by -6.87 % quarter-on-quarter, aligning with the annual decline of -5.69 %. Operating profit, while up 22.85 % compared to last year, faced a quarter-on-quarter dip of -1.48 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 5.35 %, but an expansion of 1.19 % sequentially. Other income fell by -33.98 % compared to the last quarter, despite an annual growth of 3.85 %. Interest expenses surged remarkably by 10289.06 % from the previous quarter, yet the year-over-year increase remains at a moderate 4582.39 %. Depreciation costs climbed by 1.88 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -3.01 %. Profit before tax declined annually by -9.04 % but saw a reduction from the preceding quarter by -31.96 %.
Tax expenses as a percentage of profits increased slightly by 5.09 % compared to last year, with a more notable quarter-on-quarter decrease of -1.23 %. Net profit fell by -14.51 % year-on-year but witnessed a -34.37 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -14.91 % but a quarterly fall of -34.66 %. In summary, Mankind Pharma Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 2358.566 Cr | Rs. 2529.74 Cr | Rs. 2396.57 Cr | -5.26 % | + 1.61 % |
| Expenses | Rs. 1755.46 Cr | Rs. 1777.71 Cr | Rs. 1655.64 Cr | -6.87 % | -5.69 % |
| Operating Profit | Rs. 603.11 Cr | Rs. 752.03 Cr | Rs. 740.93 Cr | -1.48 % | + 22.85 % |
| Net Profit | Rs. 487.07 Cr | Rs. 634.43 Cr | Rs. 416.38 Cr | -34.37 % | -14.51 % |
| EPS in Rs | Rs. 12.14 | Rs. 15.81 | Rs. 10.33 | -34.66 % | -14.91 % |
In reviewing Mankind Pharma Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 1.61 % year-on-year growth, although there was a slight dip of -5.26 % from the previous quarter. Expenses decreased by -5.69 % compared to the previous year, with a decrease of -6.87 % quarter-on-quarter. Operating Profit surged by 22.85 % annually, and saw a -1.48 % decrease from the last quarter.
Net Profit showed yearly decrease of -14.51 %, and experienced a -34.37 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -14.91 % annually, however dipped by -34.66 % compared to the last quarter. In essence, while Mankind Pharma Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
